The company, which specializes in artificial intelligence (AI) functionalities to aid drug discovery, could be a powerhouse, according to one market professional.
Tempus AI (NASDAQ:TEM) shares are trading higher Monday after the company announced its subsidiary, Ambry Genetics, published a peer reviewed study in Genetics in Medicine.
Top large-cap losers last week included IonQ, Tempus AI, AeroVironment, Astera Labs, Nebius, Kratos, F5, Klarna, Leonardo DRS, and First Horizon, driven by sector pullbacks, policy concerns on defense buybacks, a high-profile cyber breach, and weak earnings.
October 20, 2025 - The artificial intelligence (AI) sector continues to be a dominant force in the financial markets, driving significant gains and pushing major indices to new highs. Despite a backdrop of global economic uncertainty and geopolitical tensions, AI-related stocks have demonstrated exceptional performance throughout 2025, with some companies
Whitehawk Therapeutics shares are rising Thursday after the company announced a multi-year collaboration with Tempus AI to support the development of its oncology pipeline.
After hitting $100, Tempus AI has retreated, but shares have still provided huge returns. Multiple factors suggest that the stock could see a larger correction.
Shared stocks between Nancy Pelosi and Cathie Wood include Alphabet, Amazon, NVIDIA, and Tempus AI. They also both own stakes in private company Databricks.
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This transformative shift is redefining traditional workflows, demanding a radical re-evaluation of skill sets, and igniting critical discussions around ethics, regulation, and the very
Shares of Tempus AI Inc (NASDAQ: TEM) are trading higher Wednesday, potentially building on momentum from last week given the lack of company-specific news. Here's what investors need to know.
